Chris Kroeger
Partner @ The Aurora Funds
Waltham, United States
Chris Kroeger is a Series A investor at The Aurora Funds in Waltham focused on Health Care and Therapeutics. Chris joined Aurora in 2003 and became a Partner in 2007. Chris focuses on biopharmaceutical and medical device opportunities and brings a broad spectrum of business, clinical and scientific expertise to Aurora's investments in these sectors. Chris led or co-led syndicated investments in Cardioxyl Pharmaceuticals, Hyberbranch Medical, andNeotropix, and led Auroras's investments in Cardiofocus and Paringenix.Prior to joining Aurora, Chris trained in general surgery at Brigham and Women's Hospital/Harvard Medical School where he was involved in the medical and surgical care of transplant, trauma, vascular, cardiac and general surgical patients. He has over seven years of clinical experience in both academic and community hospital practices, and is a licensed physician in North Carolina.Chris also has significant basic science research experience primarily in signal transduction, including work on the molecular biology and genetics of apoptosis, and the transcriptional regulation of Interleukin-2 in human T-cells.Chris Previously worked with Arthur D. Little/Decision Resources, providing industry and technology analysis to biotechnology and pharmaceutical companies. Additionally, while attending business school, Chris worked in Corporate Development at Genzyme.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Chris Kroeger invests in
Stages Chris Kroeger invests in
Countries Chris Kroeger invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Therapeutics 2 (50%)
- Biotechnology 2 (50%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Series D 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cardioxyl Pharmaceuticals
|
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate.Cardioxyl hasdeveloped industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age. | $28M / Series B / Nov 13, 2012 | |
Argos Therapeutics
|
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $25M / Series D / Apr 24, 2012 | |
|
Cardioxyl Pharmaceuticals
|
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate.Cardioxyl hasdeveloped industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age. | $15M / Aug 02, 2010 | |
|
Cardioxyl Pharmaceuticals
|
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate.Cardioxyl hasdeveloped industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age. | $14.5M / Series A / Dec 06, 2006 |
Co-Investors
About The Aurora Funds
The Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential.
The Aurora Funds Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeff Clark
Managing Partner
|
|||
|
Chris Kroeger
Partner
|
|||
Doug Gooding
Venture Partner
|
|||
Richard Brown
Venture Partner
|
|||
Scott Albert
Co-Founder & Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris Kroeger invest in?
Chris Kroeger invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Kroeger?
Public channels for Chris Kroeger include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Kroeger last invest?
The most recent investment recorded for Chris Kroeger closed in Nov 2012. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
